ACELYRIN, Inc. financial data

Symbol
SLRN on Nasdaq
Industry
Pharmaceutical Preparations
Location
4149 Liberty Canyon Rd., Agoura Hills, California
State of incorporation
Delaware
Fiscal year end
December 31
Latest financial report
Q1 2024 - May 14, 2024

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 1.29 K %
Debt-to-equity 8.54 %
Return On Equity -33.9 % -115%
Return On Assets -31.2 %

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 98.4 M shares
Common Stock, Shares, Outstanding 98.9 M shares +3472%
Entity Public Float 1.46 B USD
Common Stock, Value, Issued 1 K USD
Weighted Average Number of Shares Outstanding, Basic 97.9 M shares +378%
Weighted Average Number of Shares Outstanding, Diluted 97.9 M shares +378%

Income Statement

Label TTM Value / Value Unit Change %
Research and Development Expense 246 M USD +16.8%
General and Administrative Expense 79 M USD +253%
Operating Income (Loss) -325 M USD -39.5%
Income Tax Expense (Benefit) 0 USD
Net Income (Loss) Attributable to Parent -240 M USD -6.68%
Earnings Per Share, Basic 2.82 USD/shares +95.8%
Earnings Per Share, Diluted 2.82 USD/shares +95.8%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 265 M USD -8.54%
Cash, Cash Equivalents, and Short-term Investments 679 M USD
Assets, Current 694 M USD +138%
Property, Plant and Equipment, Net 2.18 M USD +816%
Operating Lease, Right-of-Use Asset 1.15 M USD -13.7%
Assets 697 M USD +134%
Accounts Payable, Current 9.99 M USD -7.21%
Liabilities, Current 52.3 M USD +55.3%
Operating Lease, Liability, Noncurrent 1.13 M USD -13.8%
Liabilities 53.4 M USD +18%
Accumulated Other Comprehensive Income (Loss), Net of Tax -105 K USD
Retained Earnings (Accumulated Deficit) -524 M USD -84.7%
Stockholders' Equity Attributable to Parent 644 M USD
Liabilities and Equity 697 M USD +134%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -57.3 M USD -126%
Net Cash Provided by (Used in) Financing Activities 2.81 M USD
Net Cash Provided by (Used in) Investing Activities 101 M USD +112%
Common Stock, Shares Authorized 790 M shares +193%
Common Stock, Shares, Issued 98.9 M shares +357%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect 46.4 M USD +110%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 265 M USD -8.54%
Deferred Tax Assets, Valuation Allowance 98.7 M USD +316%
Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent 0.21 pure 0%
Deferred Tax Assets, Gross 99 M USD +317%
Operating Lease, Liability 1.36 M USD +3.73%
Payments to Acquire Property, Plant, and Equipment 55 K USD -76.9%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent -240 M USD -6.72%
Lessee, Operating Lease, Liability, to be Paid 1.76 M USD -6.25%
Property, Plant and Equipment, Gross 2.35 M USD
Operating Lease, Liability, Current 230 K USD
Lessee, Operating Lease, Liability, to be Paid, Year Two 398 K USD +3.11%
Lessee, Operating Lease, Liability, to be Paid, Year One 386 K USD +2.93%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 392 K USD -29.7%
Lessee, Operating Lease, Liability, to be Paid, Year Three 409 K USD +3.02%
Deferred Tax Assets, Operating Loss Carryforwards 19.6 M USD +217%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 10 M shares
Unrecognized Tax Benefits 2.35 M USD +355%
Lessee, Operating Lease, Liability, to be Paid, Year Four 280 K USD -31.5%
Additional Paid in Capital 1.17 B USD +733%
Preferred Stock, Shares Outstanding 0 shares
Depreciation, Depletion and Amortization 55 K USD
Deferred Tax Assets, Net of Valuation Allowance 252 K USD
Share-based Payment Arrangement, Expense 60.3 M USD +530%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares